One of the highlights of immunotherapy for cancer is that the protocols are personally tailored to address your individual needs. A research team at the University of Michigan recently developed a way to customize cancer vaccines that holds promise for both current treatment and long-term immunity.
“Training” the Immune System
Immunotherapy for cancer focuses on helping your own immune system battle cancer cells. The vaccine created by the University of Michigan team uses synthetic high-density lipoproteins called nanodiscs to train the immune system to recognize and attack cancer cells.
Nanodiscs use patient-specific genetic mutations, or tumor neoantigens, to trigger production of T-cells by the immune system. The T-cells then use the genetic material in the nanodiscs to target the cancer cells.
The study involved treating mice suffering from melanoma and colon cancer with a combination of checkpoint inhibitors and the nanodisc vaccine. Not only were most of the tumors eliminated, the mice remained tumor-free after the same cancer cells were reintroduced into their systems after 70 days.
University of Michigan Goes All-In on Nanodisc Research
Encouraged by the results of the test, the University of Michigan has created a biotech company named EVOQ Therapeutics to concentrate on developing and refining the nanodisc vaccine. Plans are to conduct further studies on animals before moving into clinical trials.
Issels®: Blazing the Immunotherapy for Cancer Trail
Cancer vaccines are just one of the innovative non-toxic treatments we employ at Issels®. Visit our website to learn more about our specialized testing methods and individualized integrative programs.
Cancer treatment has come a long way in the last 20 years. From immunotherapy for cancer to synthesized protein antibodies, cancer patients now have a variety of options to choose from when it comes to treatment in early or late stages.
Stanford Study Shows Promise
One of the major drawbacks of chemotherapy is the range of side effects that come with a dose strong enough to take care of a tumor. Stanford researchers have found a way to bind a synthetic protein to specific molecules in the lining of certain cells, allowing them to easily pass through without needing to be delivered via the blood stream.
Since particularly dense tumors are difficult to treat due to their lack of blood flow, many chemotherapy drugs need to be administered in high doses to get the desired effect.
The Importance of Synthetic Protein Antibodies
Much like a sponge, a tumor might absorb these special protein antibodies just by contact, leading to the saturation of the chemical within the tumor. This can cause the cancer cells to die off and the tumor to shrink, possibly eliminating the cancer causing cells completely.
All of this is done without the harmful effects of large doses of chemotherapy drugs. While these synthetic protein antibodies show promise, they could still be a few years away from the mass market.
It’s good to know that immunotherapy for cancer already exists even for late-stage patients, and new treatments are being developed by researchers to improve life expectancy and quality of life. If you would like to receive more information, get in touch with us today.
One of the drawbacks of conventional chemotherapy treatments is that the drugs kill both cancer cells and healthy cells indiscriminately. Targeted cancer therapy has been a valuable breakthrough in focusing treatment directly on cancer cells while sparing healthy ones.
Targeted Cancer Therapy: A Major Step Forward
Standard chemotherapy drugs go after cells with rapid growth and division. Problems arise because that can also be a trait of certain normal cells, and the drugs can’t tell the difference between the two.
Targeted cancer therapy is technically a form of chemo, but the way it works is more closely aligned with immunotherapy for cancer, which aids the body’s natural immune response. Instead of attacking cells globally, targeted therapy zeroes in on the gene changes that distinguish cancer cells from healthy ones.
How Does Targeted Therapy Attack Cancer Cells?
Targeted drugs have a number of “weapons” in their cancer-fighting arsenal. Some essentially starve cancer cells by cutting off blood vessel production or altering proteins within the cells. Others work in tandem with the immune system, alerting it to the presence of cancer cells that might otherwise escape detection.
While targeted cancer therapy comes with some side effects, they are generally fewer and less serious than the ones that accompany chemotherapy. Targeted therapy is sometimes used on its own, but more often it’s used in combination with conventional chemo, radiation or other treatments.
State-of-the-Art Immunotherapy for Cancer at Issels®
At Issels®, our individually tailored treatment programs include targeted therapy, cancer vaccines and other cutting-edge techniques to work with your body’s immune system. Contact us to learn more about our non-toxic protocols.
Your body’s microbiome is a network containing trillions of organisms such as bacteria, fungi and viruses. Some are positive and some are not, but they all work together to maintain a balance that keeps your system in good working condition.
In the late 1990s, scientists began to discover the crucial value of the group of organisms centered in your colon, referred to as “gut flora.” Research has found that healthy gut flora contributes to a strong immune system, which is your body’s first line of defense against foreign organisms that cause illness and disease.
Gut Flora and the Fight against Cancer
Cancer cells can often evade detection by your body’s immune system, allowing them to grow unchecked. Traditional therapies such as radiation and chemotherapy are effective, but they end up destroying healthy cells as well.
Researchers from the University of Chicago, encouraged by positive results from testing on mice, included gut flora as part of integrative immunotherapy treatments. The successful results were comparable to the beneficial effects of anti-cancer drugs.
State-of-the-Art Integrative Immunotherapy at Issels®
Integrative immunotherapy programs used at Issels® are focused on harnessing your body’s own natural defenses to destroy cancer cells. Visit our website to learn more about our cancer vaccines, immune enhancement protocols and other personalized non-toxic treatments.
The term “vaccine” is often associated with the prevention of diseases such as measles, mumps and whooping cough, many of which are contagious and usually occur in childhood. A non-toxic cancer vaccine that proactively combats existing tumors has been an effective part of our immuno-oncology protocols at Issels®.
Our vaccine therapies derive their power from a patient’s own immune system. The vaccines themselves are autologous, meaning they are prepared using the patient’s blood to incorporate potent dendritic cells.
The power of dendritic cells
Dendritic cells act as coordinators between the innate immune system, which provides the initial response to pathogens, and the adaptive immune system, which offers a long-lasting defense against the invading cells. When foreign organisms are detected, dendritic cells capture their markers, or antigens, for presentation to T-lymphocyte cells, triggering the attack on the pathogens.
What is extracorporeal photopheresis?
FDA-approved for cutaneous T-cell lymphoma, this process involves passing blood through a chamber featuring ultraviolet light, which boosts immune properties. White blood cells comprised of monocytes and lymphocytes are then extracted before the blood is returned to the body. The separated cells are cultured to become active dendritic cells and injected back into the patient, where they initiate an immune response against the tumor.
Our immuno-oncology treatment programs are personalized based on the needs of each individual patient. Specific protocols may include a non-toxic cancer vaccine, gene therapies, and other integrative treatments designed to stimulate the body’s natural immune responses. Visit our website to learn more about the effectiveness and benefits of our non-toxic, state-of-the-art immunotherapy protocols.
A new payment method for treating certain types of is cancer being tried by the country’s largest health insurer. UnitedHealth Group (UNH) has announced they will soon launch a pilot program with Houston based MD Anderson Cancer Center. Rather than multiple fee-for-service payments, UNH will pay the cancer center a single bundled payment for treatment of head and neck cancer.
Eliminate billing inefficiencies
The innovative payment plan is to last for three years. Studies have shown that paying several individual fees for testing, radiation, surgery, and chemotherapy cost more than the bundled payment method. UNH believes they can eliminate cost brought on by bureaucratic red tape and give both doctors and patients a better idea what the treatment will cost before it is underway.
Better coordination among doctors
Cancer treatment and related drug cost account for about 11 percent of UNH’s health plan expenditures. While treatment of head and neck cancer is a small part of that, it does involve physicians of various specialties. They will have to work together more closely under the bundled payment plan. If the pilot program does prove successful, UNH plans to expand it to the treatment of other types of cancer.
Our Approach is Different
These are just two of the many types of cancers that Issels® Integrative Immuno-Oncology has successfully kept in remission for thousands of patients. Without the problem of bundling by such as by some providers, Issels® is able to provide the treatment that you need instead of a “cookie cutter” approach.
For more information about the highly personalized treatment protocols, non-toxic cancer vaccines, and cell therapies used by Issels® Integrative Immuno-Oncology, contact us today. Our therapies are based on 60 years of successful cancer treatment and extensive scientific research.